Phathom Pharmaceuticals, Inc. (PHAT) Stock Grade

About Phathom Pharmaceuticals, Inc.'s fundamentals

Phathom Pharmaceuticals is a small-cap biotech company with a market capitalization of $594.6 million that has demonstrated exceptional revenue growth of 216.9% year-over-year, indicating strong commercial traction. However, the company is currently unprofitable with a net margin of -126.4% and reported a net loss in its latest annual statement, which is typical for early-stage pharmaceutical firms investing heavily in growth and product development. The company does not pay a dividend, which is consistent with its reinvestment of resources into operations. The positive return on equity of 50.5% suggests the company is generating returns on shareholder capital despite current losses, though this metric should be interpreted cautiously given the company's unprofitable status.